Compare · BDX vs IART
BDX vs IART
Side-by-side comparison of Becton Dickinson and Company (BDX) and Integra LifeSciences Holdings Corporation (IART): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and IART operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $51.45B, about 50.2x IART ($1.02B).
- Over the past year, BDX is up 3.3% and IART is down 8.1% - BDX leads by 11.4 points.
- IART has been more active in the news (13 items in the past 4 weeks vs 9 for BDX).
- Both have 25 recent analyst ratings on file.
- Company
- Becton Dickinson and Company
- Integra LifeSciences Holdings Corporation
- Price
- $191.41-1.23%
- $13.41-0.89%
- Market cap
- $51.45B
- $1.02B
- 1M return
- +5.60%
- -11.09%
- 1Y return
- +3.30%
- -8.14%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 9
- 13
- Recent ratings
- 25
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, bone and joint fixation implants in the upper and lower extremities, and bone grafts products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Latest BDX
- BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
- BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
- BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
- BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
- BD Appoints Ferass Abuzaina as Worldwide President of Surgery
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience
- EVP, Chief Revenue Officer Feld Michael sold $13,961 worth of shares (76 units at $183.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.39% to 19,644 units (SEC Form 4)
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Arthur Hu to Join BD as Chief Information and Digital Officer
- BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
Latest IART
- Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting
- INTEGRA LIFESCIENCES HOLDINGS CORPORATION IART INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 21.2% Share Drop
- SEC Form 3 filed by Integra LifeSciences Holdings Corporation
- SEC Form 8-K filed by Integra LifeSciences Holdings Corporation
- Integra Announces Pricing of Senior Secured Notes
- Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026
- Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
- Integra LifeSciences Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
- Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B